Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in CRSP.
← Back to Free Index

CRSP

Analysis as of: 2026-03-28
CRISPR Therapeutics AG
CRISPR Therapeutics develops gene-edited medicines, led by CASGEVY with Vertex, with a broader pipeline across hematology, oncology, autoimmune, cardiovascular and regenerative medicine.
ai biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

From first approval to platform proof
The key question is no longer whether gene editing can reach approval; it already has. The next rerating depends on whether the coming data prove this can become a repeatable, commercially useful platform with more than one durable franchise.

Analysis

Thesis
CRISPR Therapeutics already cleared the hardest credibility hurdle with the first approved CRISPR therapy; if 2026-2027 data convert that win into repeatable platform proof in autoimmune, oncology and in vivo editing, the stock can re-rate from cash-backed optionality to a multi-franchise gene-editing company.
Last Economy Alignment
AI should lower design and iteration cost, while CRSP owns regulated IP, approval trust and some manufacturing; biology, regulators and partner-controlled launch surfaces keep the score from being higher.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
3.7x (from 5 most recent analyses)
Reasoning
Today’s valuation still reflects cash plus platform optionality more than broad commercial proof. A higher 2031 value is justified if the company adds one real franchise beyond CASGEVY and shows that its editing engine can keep producing human data across modalities. I underwrite a premium biotech revenue multiple, but not a euphoric one, because commercialization is operationally heavy and partner control still limits direct capture.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is that scientific proof stays ahead of economic proof. CRSP has one approved therapy and a strong balance sheet, but the 2031 upside still requires non-CASGEVY human data, regulatory wins, treatment-center throughput and better direct control of commercialization surfaces. If those gates slip, the stock can remain trapped as cash plus optionality rather than rerating into a durable multi-franchise biotech.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.36
They control valuable gene-editing know-how, regulatory trust and some manufacturing, so better AI tools should help them design and advance more medicines. But biology, regulators and partner-controlled launch surfaces still set the pace, so the upside is real without being frictionless.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$70.00
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case